Compare EGY & SENS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EGY | SENS |
|---|---|---|
| Founded | 1985 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Industrial Machinery/Components |
| Sector | Energy | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 615.4M | 496.0M |
| IPO Year | 1996 | 2014 |
| Metric | EGY | SENS |
|---|---|---|
| Price | $6.03 | $9.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | $7.30 | ★ $18.38 |
| AVG Volume (30 Days) | ★ 1.2M | 587.5K |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $359,272,000.00 | $16,389,000.00 |
| Revenue This Year | $8.78 | $74.15 |
| Revenue Next Year | $29.81 | $58.60 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 19.85 |
| 52 Week Low | $3.36 | $0.41 |
| 52 Week High | $6.72 | $10.15 |
| Indicator | EGY | SENS |
|---|---|---|
| Relative Strength Index (RSI) | 51.71 | 61.52 |
| Support Level | $5.05 | $8.45 |
| Resistance Level | $6.12 | $10.07 |
| Average True Range (ATR) | 0.19 | 0.49 |
| MACD | -0.01 | -0.13 |
| Stochastic Oscillator | 27.76 | 52.96 |
VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.
Senseonics Holdings Inc is a medical technology company focused on the development and commercialization of a long-term, implantable continuous glucose monitoring (CGM) system to improve the lives of people with diabetes by enhancing their ability to manage their disease with relative ease and accuracy. Its implantable CGM system, Eversense, including Eversense E3 and Eversense 365 CGM systems, measures glucose levels via an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. The company operates through one reportable segment which derives its revenues from diabetes products and services and generates the majority of its revenue from the United States.